Sayed Aamir, MD
Endocrinology, Diabetes & Metabolism · Snellville, GANPI 1083745863
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 474 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.
Across 474 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$877
- Vivus LLC$446
- Amgen$439
- Mannkind Corporation$377
- Abbott$324
- plus $5K from 43 others
What the payments were for
- Food & beverage$8,49798%
- Education$831%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,639 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 336 | $625,282 |
| MounjaroTirzepatide | 310 | $452,420 |
| Tresiba Flextouch U-100Insulin Degludec | 135 | $152,739 |
| TrulicityDulaglutide | 65 | $115,926 |
| JardianceEmpagliflozin | 64 | $109,842 |
| RybelsusSemaglutide | 48 | $93,712 |
| FarxigaDapagliflozin Propanediol | 47 | $68,706 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $61,059 |
| JanuviaSitagliptin Phosphate | 37 | $54,715 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $52,750 |
| ProliaDenosumab | 28 | $47,654 |
| Novolog FlexpenInsulin Aspart | 74 | $29,987 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 25 | $29,220 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $28,343 |
| Bydureon BciseExenatide Microspheres | 17 | $28,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,648 | $723,681398 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $877 | $576,939400 claims |
| Boehringer IngelheimJardiance, Tradjenta | $215 | $129,49080 claims |
| MerckJanuvia, Janumet Xr, Janumet | $138 | $86,82362 claims |
| AstraZenecaFarxiga | $301 | $68,70647 claims |
| AmgenProlia | $439 | $47,65428 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $288 | $28,34319 claims |
| BayerKerendia | $220 | $19,72023 claims |
| Cequr CorporationCequr Simplicity | $175 | $9,08821 claims |
| AbbVieSynthroid | $195 | $7,52055 claims |
| IBSA Pharma Inc.Tirosint | $253 | $4,52212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $110 | $4,388369 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Snellville
- Naland ShenoySnellville$139K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.